Business
Aditxt describes itself as an innovation platform with health-related subsidiaries and programs including Adimune, Adivir, Adifem, and Pearsanta-related technologies.
Aditxt revenue nearly disappeared while losses, burn, and distress screens worsened.
The read at a glance✓ Audited against SEC data
- Business mix — Innovation platform with health subsidiariesNote
- Revenue — Revenue -97.6% to $3KWatch
- Profitability — Net loss widened to $43.1MWatch
- Cash burn — Free cash flow was -$25.7MWatch
- Balance sheet — Equity rose to $5.6MOK
- Insiders — 1 buy / 5 sells; $24K boughtWatch
- Accounting — Altman-Z distress; EQ distressWatch
Leadership changes
From Aditxt, Inc.'s own filings, the day they're filed.
- Jeffrey M. Busch · Chief Executive Officer · appointmenteff. 2026-06-05
- Rowena Albanna · Chief Operating Officer · departureeff. 2026-06-05
- Christopher J. Porcelli On · Chief People Officer · departureeff. 2026-06-02
Latest filings
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-06-23
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aditxt, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.